Paralytic peptide for use in neuromuscular therapy

Details Paralytic peptide for use in neuromuscular therapy Paralytic peptide for use in neuromuscular therapy

2006-10-10

2006-10-10

Carlson, Karen Cochrane (Department: 1653)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Reexamination Certificate

active

07119168

ABSTRACT:
The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the speciesBlarinaas a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.

REFERENCES:
patent: 5424286 (1995-06-01), Eng.
patent: 10-236963 (1998-09-01), None
Ellis et al., Properties of a toxin from the salivary gland of the shrew, Blarina brevicauda, (1955), 114(2), p. 127-137.
Kita et al., Blarina toxin, a mammalian lethal venom from the short-tailed shrew Blarina brevicauda: Isolation and characterization, PNAS, 2004, vol. 101, No. 20.
Lecchi et al., The structure of synenkephalin (Pro-Enkephalin) is dictated by three disulfide bridges, Biochemical and Biophysical Research Communications, 232, p. 800-805 (1997).
GenCore version 5.1.7, pp. 3-4 (Result 5).
S. George et al. “Blarina brevicauda,” Mammalian Species, No. 261, pp. 1-9, 3 figs. Jun. 16, 1986.
M. Phol and S. Wank. “Molecular Cloning of the Helodermin and Exendin-4 cDNAs in the Lizard.” The Journal of Biological Chemistry, vol. 273, No. 16, Issue of Apr. 17, pp. 9778-9784, 1998.
I. Martin. “Venom of the Short-Tailed Shrew (Blarina Brevicauda) as an Insect Immobilizing Agent.” Journal of Mammalogy, 62(1):189-192, 1981.
M. Dufton. “Venomous Mammals.” Pharmac. Ther. vol. 53, pp. 199-215, 1992.
T. Tomasi. “Function of Venom in the Short-Tailed Shrew Blarina Brevicauda.” Journal of Mammalogy, 59(4):852-854, 1978.
M. Pucek. “Chemistry and Pharmacology of Insectivore Venoms.” Chapter 3 of Venomous Animals and Their Venoms edited by W. Bücher, Academic Press, New York—London, 1968, pp. 43-50.
P. Christenbury “A Study of the Ecology of Blarina Brevicauda in North Carolina and of the Effect of Shrew Toxin on the Liver and Kidneys of Mice.” A thesis submitted to the Graduate Faculty of Wake Forest College in partial fulfillment of the requirements for the degree of Master of Arts in the Department of Biology, Aug. 1966, Winston-Salem, North Carolina.
Mount Allison University. “Potent Peptide Paralytic Agent.” Version 1, Jun. 2003.
Mount Allison University. “Potent Peptide Paralytic Agent.” Version 2, Jul. 2003.
M. Kita et al. “Blarina toxin, a mammalian lethal venom from the short-tailed shrewBlarina vrevicaude: Isolation and characterization.” PNAS, May 18, 2004, vol. 101, No. 20, pp. 7542-7547.
L. Zhuang et al. “Calcium-Selective Ion Channel, CaT1, Is Apically Localized in Gastrointestinal Tract Epithelia and Is Aberrantly Expressed in Human Malignancies.” Laboratory Investigation, vol. 82, No. 12, p. 1755-1764, 2002.
J-B. Peng et al. “CaT1 Expression Correlates with Tumor Grade in Prostate Cancer.” Biochemical and Biophysical Research Communication, 282, pp. 729-734, 2001.
Z. Cai et al. “Solution Structure of BmBKTx1, a New BKCa1Channel Blocker from the Chinese ScorpionButhus martensiKarsch.” Biochemistry, vol. 43, No. 13, pp. 3764-3771, 2004.
J-B. Peng et al. “Human Calcium Transport Protein CaT1.” Biochemical and Biophysical Research Communications, vol. 278, No. 2, pp. 326-332, 2000.
C. Montell. “The venerable inveterate invertebrate TRP channels.” Cell Calcium 33, pp. 409-417, 2003.
P. Lecchi et al. “The Structure of Synenkephalin (Pro-Enkephalin1-73)Is Dictated by Three Disulfide Bridges.” Biochemical and Biophysical Research Communications, vol. 232, No. 3, pp. 800-805, 1997.
E. Dekker et al. “The epithelial calcium channels, TRPV5 and TRPV6: from identification towards regulation.” Cell Calcium 33, pp. 497-507, 2003.
P. Smart. “Shrew Saliva Spells Relief? Prof. Jack Stewart makes breakthrough medical discovery.” The Argosy, Jan. 16, 2003.
“The venom of the shrew may be the new Botox.” National Post, Science Section (Biochemistry), Dec. 20, 2002.

Affiliated with

Also associated with

Rating

Paralytic peptide for use in neuromuscular therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Paralytic peptide for use in neuromuscular therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Paralytic peptide for use in neuromuscular therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3715828